260 related articles for article (PubMed ID: 31278686)
1. Differential expression of RET isoforms in normal thyroid tissues, papillary and medullary thyroid carcinomas.
Ramone T; Romei C; Ciampi R; Tacito A; Piaggi P; Torregrossa L; Ugolini C; Elisei R
Endocrine; 2019 Sep; 65(3):623-629. PubMed ID: 31278686
[TBL] [Abstract][Full Text] [Related]
2. Differential roles of RET isoforms in medullary and papillary thyroid carcinomas.
Lian EY; Maritan SM; Cockburn JG; Kasaian K; Crupi MJ; Hurlbut D; Jones SJ; Wiseman SM; Mulligan LM
Endocr Relat Cancer; 2017 Jan; 24(1):53-69. PubMed ID: 27872141
[TBL] [Abstract][Full Text] [Related]
3. Higher
Mulè C; Ciampi R; Ramone T; Prete A; Matrone A; Cappagli V; Torregrossa L; Basolo F; Elisei R; Romei C
Biomolecules; 2021 Oct; 11(10):. PubMed ID: 34680178
[TBL] [Abstract][Full Text] [Related]
4. C-cell and thyroid epithelial tumours and altered follicular development in transgenic mice expressing the long isoform of MEN 2A RET.
Reynolds L; Jones K; Winton DJ; Cranston A; Houghton C; Howard L; Ponder BA; Smith DP
Oncogene; 2001 Jul; 20(30):3986-94. PubMed ID: 11494127
[TBL] [Abstract][Full Text] [Related]
5. Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland.
Ciampi R; Romei C; Pieruzzi L; Tacito A; Molinaro E; Agate L; Bottici V; Casella F; Ugolini C; Materazzi G; Basolo F; Elisei R
J Endocrinol Invest; 2017 Jan; 40(1):55-62. PubMed ID: 27535135
[TBL] [Abstract][Full Text] [Related]
6. LRIG1 negatively regulates RET mutants and is downregulated in thyroid cancer.
Lindquist D; Alsina FC; Herdenberg C; Larsson C; Höppener J; Wang N; Paratcha G; Tarján M; Tot T; Henriksson R; Hedman H
Int J Oncol; 2018 Apr; 52(4):1189-1197. PubMed ID: 29436694
[TBL] [Abstract][Full Text] [Related]
7. Differential expression of RET receptor isoforms in the olfactory system.
Kaplinovsky T; Cunningham AM
Neuroscience; 2011 Feb; 175():49-65. PubMed ID: 21118713
[TBL] [Abstract][Full Text] [Related]
8. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
[TBL] [Abstract][Full Text] [Related]
9. Relative expression of the RET9 and RET51 isoforms in human pheochromocytomas.
Le Hir H; Charlet-Berguerand N; Gimenez-Roqueplo A; Mannelli M; Plouin P; de Franciscis V; Thermes C
Oncology; 2000 May; 58(4):311-8. PubMed ID: 10838497
[TBL] [Abstract][Full Text] [Related]
10. RET/PTC fusion gene rearrangements in Japanese thyroid carcinomas.
Nibu K; Otsuki N; Nakao K; Sugasawa M; Rothstein JL
Eur Arch Otorhinolaryngol; 2005 May; 262(5):368-73. PubMed ID: 15368067
[TBL] [Abstract][Full Text] [Related]
11. One hundred and seven family members with the rearranged during transfection V804M proto-oncogene mutation presenting with simultaneous medullary and papillary thyroid carcinomas, rare primary hyperparathyroidism, and no pheochromocytomas: is this a new syndrome--MEN 2C?
Shifrin AL; Xenachis C; Fay A; Matulewicz TJ; Kuo YH; Vernick JJ
Surgery; 2009 Dec; 146(6):998-1005. PubMed ID: 19958926
[TBL] [Abstract][Full Text] [Related]
12. A Homozygous RET K666N Genotype With an MEN2A Phenotype.
Jaber T; Hyde SM; Cote GJ; Grubbs EG; Giles WH; Stevens CA; Dadu R
J Clin Endocrinol Metab; 2018 Apr; 103(4):1269-1272. PubMed ID: 29408964
[TBL] [Abstract][Full Text] [Related]
13. [Expressions of wildtype-RET and RET/PTC rearrangements in sporadic adult papillary thyroid carcinoma and their clinicopathologic correlation].
Zhu XL; Zhou XY; Zhang TM; Zhu XZ
Zhonghua Bing Li Xue Za Zhi; 2006 Feb; 35(2):87-91. PubMed ID: 16630482
[TBL] [Abstract][Full Text] [Related]
14. A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma.
Romei C; Ciampi R; Elisei R
Nat Rev Endocrinol; 2016 Apr; 12(4):192-202. PubMed ID: 26868437
[TBL] [Abstract][Full Text] [Related]
15. Transcript level modulates the inherent oncogenicity of RET/PTC oncoproteins.
Richardson DS; Gujral TS; Peng S; Asa SL; Mulligan LM
Cancer Res; 2009 Jun; 69(11):4861-9. PubMed ID: 19487296
[TBL] [Abstract][Full Text] [Related]
16. Diversity of mutations in the RET proto-oncogene and its oncogenic mechanism in medullary thyroid cancer.
Hedayati M; Zarif Yeganeh M; Sheikholeslami S; Afsari F
Crit Rev Clin Lab Sci; 2016 Aug; 53(4):217-27. PubMed ID: 26678667
[TBL] [Abstract][Full Text] [Related]
17. Medullary and papillary tumors are frequently associated in the same thyroid gland without evidence of reciprocal influence in their biologic behavior.
Biscolla RP; Ugolini C; Sculli M; Bottici V; Castagna MG; Romei C; Cosci B; Molinaro E; Faviana P; Basolo F; Miccoli P; Pacini F; Pinchera A; Elisei R
Thyroid; 2004 Nov; 14(11):946-52. PubMed ID: 15671773
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of L-Type Amino Acid Transporter 1 (LAT1) and 2 (LAT2): Novel Markers of Neuroendocrine Tumors.
Barollo S; Bertazza L; Watutantrige-Fernando S; Censi S; Cavedon E; Galuppini F; Pennelli G; Fassina A; Citton M; Rubin B; Pezzani R; Benna C; Opocher G; Iacobone M; Mian C
PLoS One; 2016; 11(5):e0156044. PubMed ID: 27224648
[TBL] [Abstract][Full Text] [Related]
19. Risk Profile of the RET A883F Germline Mutation: An International Collaborative Study.
Mathiesen JS; Habra MA; Bassett JHD; Choudhury SM; Balasubramanian SP; Howlett TA; Robinson BG; Gimenez-Roqueplo AP; Castinetti F; Vestergaard P; Frank-Raue K
J Clin Endocrinol Metab; 2017 Jun; 102(6):2069-2074. PubMed ID: 28323957
[TBL] [Abstract][Full Text] [Related]
20. Expression of RET in follicular cell-derived tumors of the thyroid gland: prevalence and implication of morphological type.
Inaba M; Umemura S; Satoh H; Abe Y; Kurokawa K; Sakai H; Osamura RY
Pathol Int; 2003 Mar; 53(3):146-53. PubMed ID: 12608895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
